Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dixyrazine is a typical antipsychotic of the phenothiazine group, structurally classified as a phenothiazine with a piperazine side chain. It acts primarily as an antagonist at dopamine D2 receptor and histamine H1 receptor, giving it both neuroleptic (antipsychotic) and antihistaminic properties[1][7]. Dixyrazine was first introduced in Germany in 1969 and has been used mainly for the management of schizophrenia, other psychoses, anxiety states, agitation, and as an antiemetic[1][4][5]. It also exhibits sedative effects. The drug is administered orally or by intramuscular injection in doses typically ranging from 12.5 to 75 mg per day[1][5]. Its mechanism of action involves antagonism at dopamine D2 receptor (reducing psychotic symptoms) and histamine H1 receptor (contributing to its sedative effect)[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dixyrazine.